-
Innovation Ranking
NewInnovation Ranking – NGM Biopharmaceuticals Inc
NGM Biopharmaceuticals Inc (NGM Bio) operates as a clinical-stage bio pharmaceutical company that develops pipeline of biological therapeutics for the treatment of cardio-metabolic, immuno-oncology, retinal and liver diseases and ophthalmic diseases. The company’s pipeline products include NGM707, NGM831, NGM438, NGM120, NGM621, MK-3655 and Aldafermin. Its NGM707 is a novel dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript and NGM831 is the potential to fight tumors by shifting myeloid cells...
-
Product Insights
NewNet Present Value Model: NGM Biopharmaceuticals Inc’s NGM-120
Empower your strategies with our Net Present Value Model: NGM Biopharmaceuticals Inc's NGM-120 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NGM-707 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-707 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NGM-707 in Ovarian Cancer Drug Details: NGM-707 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NGM-707 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-707 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NGM-707 in Breast Cancer Drug Details: NGM-707 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NGM-707 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-707 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NGM-707 in Non-Small Cell Lung Cancer Drug Details: NGM-707 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cisplatin + Vinblastine Sulphate) in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cisplatin + Vinblastine Sulphate) in Lymphoma Drug Details: Cisplatin in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cisplatin + Vinblastine Sulphate) in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cisplatin + Vinblastine Sulphate) in Melanoma Drug Details: Cisplatin in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Temuterkib in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Temuterkib in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Temuterkib in Metastatic Colorectal Cancer Drug Details: LY-3214996 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacmilimab in Skin Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacmilimab in Skin Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacmilimab in Skin Cancer Drug Details: CX-072 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XB-002 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XB-002 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XB-002 in Non-Small Cell Lung Cancer Drug Details: XB-002...